MTOR and hepatocellular carcinoma: These observations prompted us to investigate the potential antitumor effects of vinorelbine in combination with mTOR inhibitors (everolimus and sirolimus) in the HCC PDX models, with each exhibiting varying levels of sensitivity to either vinorelbine or mTOR inhibitors.